Diabetes mellitus in β-thalassemia major patients

  • Riadi Wirawan
  • Santy Setiawan
  • Simon Kusnandar
  • Bulan G. Munthe
Abstract viewed: 1599 times
PDF downloaded: 407 times


β-thalassemia major is a disease caused by β polypeptide chain synthesis disorder which is inherited as an autosomal recessive from both parents which is marked by little or no β globin chain synthesis. Medication for β thalassemia major patients is by repeated blood transfusions, which causes hemochromatosis. Hemochromatosis can occur in various organs including the pancreas. The aim of the study was to assess the alteration of plasma glucose concentration and the hemochromatosis prevalence. Fasting plasma glucose concentration and serum ferritin examination were measured in 115 β thalassemia major patients with ages between 10-23 years who were out-patients in the Thalassemia Centre, Department of Child Health, Medical School, University of Indonesia / Dr. Cipto Mangunkusumo General Hospital, Jakarta. The plasma glucose concentration examination was conducted by the GDH enzymatic method, with American Diabetes Association (ADA) criteria in the evaluation, while the serum ferritin examination was conducted with the microparticle enzyme immuno assay (MEIA) method. All patients had hemochromatosis, 14.8% of the patients had impaired fasting glucose level and 2.6% of the patients showed indications of diabetes mellitus. β thalassemia major patients who receive frequent transfusions will develop hemochromatosis that will in turn impair the pancreatic function. (Med J Indones 2003; 12: 87-93)

Keywords : β thalassemia major, hemochromatosis, diabetes mellitus

How to Cite
Wirawan R, Setiawan S, Kusnandar S, Munthe BG. Diabetes mellitus in β-thalassemia major patients. Med J Indones [Internet]. 2003May1 [cited 2020Sep.27];12(2):87-3. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/94
Clinical Research

Most read articles by the same author(s)